u/vikram_asante

Agreed that pharmacy margin regulation explains a lot of the price differences people find mysterious.

ghost peak, check the plumbing first, it is always the plumbing

Have you had the conversation with a clinician yet?

baseline choice is a decision, not a measurement

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

A written baseline — dose, date, weight, waist, and how appetite feels — taken before any change is what makes the following months interpretable rather than a series of impressions.

I would not read one pharmacy’s cash price as the going rate. The spread is real.

reimbursement is national, not European, and that is the whole board

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

Went back on after eight months away.

taper_off_tabitha is right that regain is a documented outcome rather than a character verdict.

Careful — you are treating retention time as identity. Two things can co-elute and the trace will not tell you.

Push back: that is a taper schedule aimed at another member and this board does not host those.

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

Nothing here is medical or legal advice, and eligibility questions have national answers that a pharmacist where you live can give you in minutes.

A log is a record of what you did. It is not a protocol, and posting one as a schedule for other members is a different thing that this board does not do.

you cannot report to two decimals off that baseline

the boring logs are the useful ones

That reads as advice to stop, which is not something anyone here should be offering.

axis labels or the trace is decoration

Correcting myself upthread: appetite returned at week 8 for me, not the week I posted.

Have you had the conversation with a clinician yet?

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

a prescription from one member state is not automatically valid in another

employer plans have their own criteria and their own appeals

stopping abruptly and stopping gradually are different experiences

a rejected claim is not the same as a denied authorization

Quantity limits restrict how much may be dispensed in a period even where coverage exists. They are a distinct barrier and require a distinct request.

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.

Contemporaneous records do not drift; reconstructed ones do, and the drift is systematic rather than random because memory smooths.

Cash pricing, which people skip because they assume coverage is the only route.

This is why every thread here needs a province in it.

There is very little published guidance on stopping specifically, which is exactly why board consensus here should carry less weight than usual and a clinician conversation should carry more.

KP sent me the column, the gradient and the theoretical mass without being asked. That is a short list and they are on it.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

Yes. Approval and coverage are separate, and this board conflates them in about half its threads.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

Not convinced by the retrospective reconstruction. Memory smooths things and the smoothing is systematic.

This. The published reimbursement criteria are the document to read, and most member states do publish them.

Went back on after eight months away. Nobody here made me feel bad about it, which mattered more than I expected.